Combination therapy for sporadic inclusion body myositis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study evaluates the efficacy and safety of a combination therapy using Pozelimab and Cemdisiran in patients diagnosed with sporadic inclusion body myositis (sIBM). A total of 10 participants aged 45 to 75 will receive subcutaneous injections of Pozelimab and Cemdisiran every four weeks for a duration of 104 weeks. Initial injections will be administered by study staff, with subsequent doses potentially given at home after proper training. Participants will be monitored for safety and efficacy throughout the study period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Age ≥45 years to 75 years of age 2. Diagnosed with sIBM based on the ENMC IBM Research Diagnostic Criteria 3. Willing and able to comply with clinic visits and study-related procedures. 4. Provide informed consent signed by the study patient or legally acceptable representative.

  5\. Able to understand and complete study-related questionnaires. 6. Able to ambulate at least 20 ft/6 meters with or without assistive device Once arising from the chair, the participant may use any walking device, i.e. walker/frame, cane, crutches, or braces. They cannot be supported by another person and cannot use furniture or walls for support.

  7\. If female, the subject must be: (a) surgically sterilized via hysterectomy, bilateral oophorectomy, or bilateral tubal ligation. or (b) of childbearing potential and using a birth control method, such as:

  •Combined (estrogen and progestogen-containing) hormonal. contraception associated with inhibition of ovulation:

  o Oral
  * Intravaginal
  * Transdermal

    * Progestogen-only hormonal contraception associated with inhibition of ovulation:
  * Oral
  * Injectable
  * Implantable

    • Intrauterine device

    • Intrauterine hormone-releasing system

    • Bilateral tubal occlusion
    * Vasectomized partner
    * Sexual abstinence or of non-childbearing potential (i.e., no menses for ≥12 consecutive months without any other underlying medical cause) The subject must agree to continue using her selected method of birth control with her sexual partner during the study and for 120 days after study completion.

      8\. If male, the subject must have had a vasectomy or must use a reliable method of birth control with their partner or maintain total abstinence from sexual intercourse. The subject must agree to continue using his selected method of birth control with his sexual partner during the study and for 120 days after the study completion.

Exclusion Criteria:

* 1\. Other neurological conditions (e.g., hemiplegia post-stroke, Parkinson's Disease) or musculoskeletal conditions (e.g., severe osteoarthritis) causing mobility impairment.

  2\. Any known active malignancy 3. Significant illness or history of significant illness that, in the investigator's opinion, may adversely affect the patient's participation in this study.

  4\. Any previous treatment with a complement inhibitor 5. History of meningococcal disease 6. No documented meningococcal and pneumococcal vaccination within 5 years prior to screening visit unless vaccination will be administered during the screening period and prior to initiation of study treatment.

  7\. Known contraindication to meningococcal (group ACWY conjugate and group B vaccines) and pneumococcal vaccines.

  8\. Subject unwilling to receive meningococcal and pneumococcal vaccinations. 9. Patients with screening serum ALT levels \>3×ULN and/or total bilirubin \>2×ULN (unless bilirubin elevation is due to suspected Gilbert's syndrome).

  10\. Active or recent systemic infection within 2 weeks prior to Baseline. 11. Pregnant, planning to become pregnant, or lactating female subjects. 12. Treatment with an experimental drug within 30 days or 5 half-lives of the experimental drug.

  13\. Participation in another concurrent interventional clinical trial. 14. Subjects with functional and anatomic asplenia 15. Subjects with positive tests for hepatitis B, hepatitis C, or HIV at screening 16. Presence of active or latent tuberculosis 17. Presence of any other form of myositis or myopathy or myositis overlap with other autoimmune diseases 18. Presence of other autoimmune or autoinflammatory diseases

Where it's running

• Austin Neuromuscular Center
  Austin, Texas, United States Recruiting
• Austin Neuromuscular Center
  Austin, Texas, United States Recruiting

Study contacts

• Principal investigator: Yessar Hussain, MD — Austin Neuromuscular Center
• Study coordinator: Yessar Hussain, MD
• Email: research@austinneuromuscle.com
• Phone: 5129200140

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MTS109 treatment for refractory autoimmune diseases

  This trial tests whether MTS109 (an mRNA-LNP given by subcutaneous injection) is safe and tolerable in adults with moderate to severe autoimmune diseases that have not responded to standard treatments.

  Recruiting Early Phase 1 Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT07526350

• AZD0120 CD19/BCMA CAR T-cell therapy for systemic sclerosis, inflammatory myopathies, and difficult-to-treat rheumatoid arthritis

  This trial will try a dual-targeting CD19/BCMA CAR T-cell treatment (AZD0120) in adults with systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis to see if it is safe and well tolerated.

  Recruiting at 5 sites Phase 1/2 AstraZeneca · Tucson, Arizona and 26 other locations · NCT07295847

• Phase 1 safety test of XmAb657 in healthy adults and people with myositis, scleroderma, or Sjögren's

  This study will test whether subcutaneous injections of XmAb657 are safe and well tolerated in healthy adults and people with autoimmune diseases such as idiopathic inflammatory myopathies, systemic sclerosis, or primary Sjögren's syndrome.

  Recruiting Phase 1 Xencor, Inc. · Melbourne · NCT07284797

• Eye injection of pozelimab for geographic atrophy in adults

  This study will test whether injections of pozelimab into the eye are safe and well tolerated in adults with geographic atrophy from age-related macular degeneration.

  Recruiting at 9 sites Phase 1 Regeneron Pharmaceuticals · Lakewood, Colorado and 8 other locations · NCT07230834

• Pozelimab + cemdisiran for adults with PNH whose current treatment isn't working

  This trial tests whether combining pozelimab and cemdisiran can better reduce hemolysis in adults with PNH whose C5 inhibitor treatment isn’t controlling their disease.

  Recruiting at 20 sites Phase 3 Regeneron Pharmaceuticals · Ribeirão Preto, São Paulo and 19 other locations · NCT07154745

• Pozelimab safety in children 1 to 5 with CHAPLE disease

  This trial will test whether pozelimab is safe and tolerable in children ages 1 to 5 who have CHAPLE disease.

  Recruiting Phase 4 Regeneron Pharmaceuticals · Istanbul · NCT07142343

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.